Acquiring Company
Jazz Pharmaceuticals
Acquired Company
Actio Biosciences
Dublin
San DiegoManufacturingBiotechnologyHealth CareTherapeuticsPharmaceuticalBiopharmaBiotechnologyHealth CareTherapeuticsDescription
Jazz Pharmaceuticals has agreed to acquire Actio Biosciences, a biotechnology company focused on rare epilepsies, in a deal valued at over $1.3 billion. The agreement includes an upfront payment and milestone incentives based on Actio's research success. This acquisition enhances Jazz's research pipeline in neuroscience and strengthens its position in treating severe epilepsy. The deal is expected to close within the year.
Related People
M&A Insights
Based on deal dataFrequently asked
Who acquired Actio Biosciences?
Actio Biosciences was acquired by Jazz Pharmaceuticals, based in Dublin. The deal was reported on August 10, 2026. Jazz Pharmaceuticals is a pharmaceutical company known for its focus on a range of medical conditions, including sleep disorders, epilepsy, and cancer. Jazz Pharmaceuticals is publicly traded (JAZZ) and operates in Manufacturing.
When did Jazz Pharmaceuticals acquire Actio Biosciences?
Jazz Pharmaceuticals's acquisition of Actio Biosciences was reported on August 10, 2026. Jazz Pharmaceuticals has agreed to acquire Actio Biosciences, a biotechnology company focused on rare epilepsies, in a deal valued at over $1.3 billion. The agreement includes an upfront payment and milestone incentives based on Actio's research success. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Actio Biosciences do?
Actio Biosciences is a biotechnology company leveraging a novel platform approach to genetics and precision medicine to develop new therapeutics that target shared underlying biology in both rare and common diseases. It is privately held, operating in Biotechnology, and is based in San Diego.